Docoh
Loading...

VNRX VolitionRX

VolitionRX Ltd. is a multi-national life sciences company, which engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid. The company was founded on August 5, 2010 and is headquartered in Austin, TX.

Company profile

Ticker
VNRX
Exchange
CEO
Cameron John Reynolds
Employees
Incorporated
Location
Fiscal year end
Former names
STANDARD CAPITAL CORP
SEC CIK
IRS number
911949078

VNRX stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

11 May 21
14 Jun 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from VolitionRX earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 33.06M 33.06M 33.06M 33.06M 33.06M 33.06M
Cash burn (monthly) (positive/no burn) (positive/no burn) 2.03M 1.79M 2.06M 1.49M
Cash used (since last report) n/a n/a 5.01M 4.41M 5.07M 3.67M
Cash remaining n/a n/a 28.06M 28.65M 27.99M 29.39M
Runway (months of cash) n/a n/a 13.8 16.0 13.6 19.8

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
28 May 21 Terrell Jason Bradley MD Common Stock Sell Dispose S No No 3.54 10,000 35.4K 24,949
17 May 21 Innes Guy Archibald Common Stock Buy Aquire P No No 3.47 50,000 173.5K 1,534,975
14 May 21 Innes Guy Archibald Common Stock Buy Aquire P No No 3.29 100,000 329K 1,484,975
14 May 21 Kim Nguyen Common Stock Buy Aquire P No No 3.2 2,000 6.4K 2,500
1 May 21 Salvatore Thomas Butera Common Stock Grant Aquire A No No 0 150,000 0 150,000
25 Mar 21 Salvatore Thomas Butera Common Stock Sale back to company Dispose D No No 0 15,000 0 0

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

14.3% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 45 45
Opened positions 4 4
Closed positions 4 13 -69.2%
Increased positions 21 15 +40.0%
Reduced positions 8 13 -38.5%
13F shares
Current Prev Q Change
Total value 46.64M 39.53M +18.0%
Total shares 7.54M 6.79M +11.0%
Total puts 0 600 EXIT
Total calls 24.8K 18.7K +32.6%
Total put/call ratio 0.0
Largest owners
Shares Value Change
Lagoda Investment Management 2.55M $9.91M +7.3%
BLK Blackrock 1.87M $7.29M +5.5%
MS Morgan Stanley 491.78K $1.91M +42.7%
Vanguard 458.19K $1.78M -1.4%
Geode Capital Management 404.96K $1.58M +14.1%
STT State Street 372.23K $1.45M +43.7%
NTRS Northern Trust 318.48K $1.24M +7.2%
Nuveen Asset Management 159.77K $622K +29.2%
Bridgeway Capital Management 155.5K $605K +56.4%
Gsa Capital Partners 115.94K $451K +2.4%
Largest transactions
Shares Bought/sold Change
Lagoda Investment Management 2.55M +174.37K +7.3%
MS Morgan Stanley 491.78K +147.21K +42.7%
STT State Street 372.23K +113.2K +43.7%
BLK Blackrock 1.87M +97.38K +5.5%
Bridgeway Capital Management 155.5K +56.1K +56.4%
JPM JPMorgan Chase & Co. 73.65K +54.12K +277.1%
Geode Capital Management 404.96K +50.01K +14.1%
Ovata Capital Management 2.47K -47.53K -95.1%
GS Goldman Sachs 11.82K -46.22K -79.6%
VIRT Virtu Financial 44.39K +44.39K NEW

Financial report summary

?
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: accessible, aim, assay, Butera, cancelled, cooperation, deferred, distributor, ELISA, flat, Forterre, fourth, furnish, Gael, Gaetan, Gastrointestinal, hope, immunosorbent, improve, inducement, ineffective, insurance, IP, kit, main, maximal, Michel, multiple, omitted, opportunity, partly, patient, payroll, phenomenon, prepaid, presence, prevalence, recurrence, redacted, repurchased, resignation, routine, RUO, Salvatore, save, settled, settlement, SRL, tax, Terig, underwritten, wholly, withheld
Removed: acknowledged, August, automated, collaborative, collaborator, criteria, David, expiration, exquisite, free, handling, installment, insufficient, kind, level, liquid, Michigan, mitigation, national, offer, originally, partner, predict, redefine, resulting, retired, satisfied, sponsorship, subsequently, Tecan, undertaken, Vanston